Kyle Concannon
Overview
Explore the profile of Kyle Concannon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morris B, Heeke S, Xi Y, Diao L, Wang Q, Rocha P, et al.
bioRxiv
. 2024 Aug;
PMID: 39211077
Introduction: A hallmark of small cell lung cancer (SCLC) is its recalcitrance to therapy. While most SCLCs respond to frontline therapy, resistance inevitably develops. Identifying phenotypes potentiating chemoresistance and immune...
2.
Zhang B, Lewis W, Stewart C, Morris B, Solis L, Serrano A, et al.
JTO Clin Res Rep
. 2024 Feb;
5(2):100623.
PMID: 38357092
Introduction: NSCLC transformation to SCLC has been best characterized with -mutant NSCLC, with emerging case reports seen in , , and -altered NSCLC. Previous reports revealed transformed SCLC from -mutant...
3.
Heeke S, Gay C, Estecio M, Tran H, Morris B, Zhang B, et al.
Cancer Cell
. 2024 Jan;
42(2):225-237.e5.
PMID: 38278149
Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given...
4.
Pan K, Concannon K, Li J, Zhang J, Heymach J, Le X
Nat Rev Clin Oncol
. 2023 Aug;
20(10):716-732.
PMID: 37592034
The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC), largely owing to the improved control of systemic disease provided by immune-checkpoint inhibitors and novel targeted therapies, have highlighted...
5.
Concannon K, Morris B, Gay C, Byers L
Mol Cell
. 2023 Jan;
83(5):660-680.
PMID: 36669489
Targeted therapy and immunotherapy have revolutionized cancer treatment. However, the ability of cancer to evade the immune system remains a major barrier for effective treatment. Related to this, several targeted...
6.
Rothenberg S, Concannon K, Cullen S, Boulay G, Turke A, Faber A, et al.
Elife
. 2015 Feb;
4.
PMID: 25686219
Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression but it is invariably followed by drug resistance. In characterizing early transcriptional changes following drug treatment of mutant...